26 results about "Troponin" patented technology

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The present disclosure provides devices, systems incorporating the devices, methods for manufacturing the devices, and methods of using the devices for carrying out assays, such as chemical and / or biological assays. The systems include a wearable device including a biosensor having a plurality of electrodes. A functionalized coating is coupled to an electrode of the biosensor. A controller may sense an electrochemical response of the biosensor, and determine whether a health-related biomarker is present based on the electrochemical response. The functionalized coating may include a sulfonated block copolymer such as sulfonated styrene-isobutylene-styrene (SIBS). The health-related biomarker may include cardiac troponin I (cTnI).

The invention relates to the field of antibodies, in particular to an anti-troponin I monoclonal antibody and application thereof, performance analysis of a purified electrophoretogram of the antibody and a kit coupled with a monoclonal antibody HK401 coated magnetic particle component shows that the monoclonal antibody has excellent performance in cTni detection, and the cTni detection sensitivity is high. The method can be used as an object for further production and optimization.

The traditional Chinese medicine composition is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 3 to 9 parts of rhizoma chuanxiong, 3 to 7 parts of rhizoma atractylodis, 6 to 14 parts of rhizoma cyperi, 6 to 14 parts of medicated leaven, 3 to 7 parts of euphorbia helioscopia, 10 to 20 parts of poria cocos, 8 to 12 parts of fructus trichosanthis, 8 to 12 parts of radix salviae miltiorrhizae, 8 to 12 parts of herba epimedii, 3 to 9 parts of pepper, 8 to 12 parts of herba patriniae and 8 to 12 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating acute myocardial infarction, a remarkable effect is achieved on PCI postoperative improvement of acute myocardial infarction, troponin and creatine kinase isoenzyme indexes are reduced, and the left ventricular ejection fraction is in a normal range after cardiac color ultrasound display treatment. Through comprehensive conditioning, symptoms such as chest distress, chest pain, shortness of breath and hypodynamia of patients are improved, cardiac function recovery is promoted, complications such as restenosis and heart failure are prevented, and life quality is improved.

This invention relates to the field of biomedical technology, specifically to the application of PTPRM in the treatment and / or prevention of septic cardiomyopathy. This application found that the expression level of PTPRM was significantly reduced in the cardiac tissue of a CLP model, and further verified that overexpression of PTPRM significantly improved the survival rate of the CLP model. Furthermore, the reduction in PAT caused by CLP modeling, as well as the increases in RVDFW, RVSFW, LVSFW, LVDFW, IVS-s, and IVS-d, were also improved. In addition, overexpression of PTPRM can also reduce the expression level of cardiac troponin (cTNT) and right ventricular wall thickness. Therefore, PTPRM can be used as a target for the treatment of septic cardiomyopathy.

This invention describes a novel gene regulatory sequence containing the promoter and enhancer sequences of the human cardiac troponin T gene (TNNT2) that selectively induces expression in cardiomyocytes. This novel TNNT2 promoter / enhancer composition can be used to induce adeno-associated virus gene expression, construct cell-type-specific expression vectors, or perform cardiac-specific transgenesis. The use of this novel promoter / enhancer composition is demonstrated by the expression of mAKAP shRNA and a mAKAP-derived anchor-disrupting peptide useful for the treatment of heart failure.

The invention relates to the technical field of immunoassay, and discloses a chemiluminescence immunoassay method for high-sensitivity detection of cardiac troponin I. The chemiluminescence immunoassay method comprises the following steps: fixing an anti-cardiac troponin I capture antibody based on a solid phase carrier; a sample to be detected is in contact with the solid phase carrier coated with the capture antibody, a detection antibody is added, the detection antibody is connected with a signal marker, and the signal marker is a compound formed by loading alkaline phosphatase on a nano material or is the nano material; a chemiluminescent substrate is added, and the chemiluminescent substrate is a compound based on 1, 2-dioxetane; detecting a chemiluminescence signal so as to quantify cardiac troponin I; according to the invention, the problem of non-uniform detection of degradation fragments is solved, and the diagnosis window period is prolonged; meanwhile, extremely high detection sensitivity, signal-to-noise ratio and stability are realized, and the kit is suitable for early and accurate diagnosis of myocardial injury.

Embodiments of the present invention relates to an apparatus for monitoring cardiovascular diseases comprising an implantable mechanical sensor (1) for detecting strain levels of a heart; an implantable or wearable microneedle-based chemical sensor (2) for detecting level of cardiac biomarkers such as troponin; at least a wireless communication unit for transmitting the mechanical sensor (1) and / or chemical sensor (2) readings.

The invention relates to the technical field of biomedicine and cardiovascular disease treatment, and discloses application of an Aralar myocardial overexpression virus in preparation of a medicine for treating heart failure. The related product is a gene therapy preparation containing an effective amount of AAV9-cTnT-Aralar, and can be matched with pharmaceutically acceptable carriers, diluents and other auxiliary materials, and the preparation is an injection type. The preparation method comprises the following steps: firstly, constructing a cardiac troponin T-carrying promoter and an AAV9 carrier of an Aralar coding nucleic acid to form a recombinant adeno-associated virus, and then matching the virus with proper auxiliary materials to prepare the preparation. The product can be used for treating heart failure accompanied with mitochondrial dysfunction, can realize heart targeted delivery and myocardial cell specific overexpression of Aralr, relieves the heart failure course by improving the myocardial cell mitochondrial function and dynamic balance, and is good in preparation stability, convenient in administration and adaptive to clinical application requirements.

The application discloses an antibody for detecting cardiovascular diseases and application thereof, and belongs to the technical field of biological medicine. The monoclonal antibody or antigen binding fragment thereof provided by the application can specifically bind to a specific antigen epitope (SEQ ID NO:1) of human cardiac troponin I (cTnI) and has no cross reaction with skeletal muscle troponin I. The application further discloses the CDR sequences of the heavy chain and light chain variable regions of the antibody, a coding gene, a preparation method and application thereof. An ELISA detection kit containing the antibody can specifically recognize cTnI in a blood sample, has good linearity in the range of 0.01-50 ng / mL, has a false negative rate of 0 for serum detection of patients with acute myocardial infarction, and has a low false positive rate for serum detection of healthy people. The antibody and the kit have important application value in rapid and accurate diagnosis of cardiovascular diseases such as acute myocardial infarction.

This invention discloses a novel cardiac troponin I combined detection kit, belonging to the field of reagent kit technology. It includes a reagent shell with a mounting base fixed inside. The mounting base has a set of test tube holes inside, and a set of support components at the bottom of the mounting base to raise the height of the test tubes inside the test tube holes. In this novel cardiac troponin I combined detection kit, rotating a transmission wheel causes a threaded rod to move a transmission block. A support rod and connecting block move a connecting plate upwards, causing a top rod to slide inside the test tube holes. This allows the test tubes inside the holes to move upwards, raising the top of the test tubes above the top surface of the reagent shell for easy handling. A first compression spring pushes a positioning hook, causing its tip to engage with a slot. Simultaneously, a second compression spring pushes a pressure rod to support the positioning rod, positioning it between the positioning hook and the pressure rod, thus fixing the position of the top cover.

The present invention relates to an improved variant monoclonal antibody binding to cardiac troponin T and having a better KD than the parent monoclonal antibody 11-7.

The present invention relates to a method for assessing asymptomatic heart failure said method comprising cMyBP-C (Myosin binding protein C, cardiac type), and optionally the level of at least one further biomarker selected from the group consisting of MyL7 (Myosin light chain 7), at least one cardiac Troponin, Angiopoietin-2 (Ang-2), and at least one BNP -type peptide in a sample from the subject. The present invention further relates to computer-implemented methods, databases, devices, kits and uses related thereto.

The present application relates to the technical field of immunology and meat product adulteration meat source identification, and provides a hybridoma cell strain, an anti-fox skeletal muscle troponin monoclonal antibody produced by the hybridoma cell strain and application of the antibody, the preservation name of the hybridoma cell strain is: the hybridoma cell strain skTn-3A4 of the anti-fox skeletal muscle troponin monoclonal antibody, the preservation place is China Center for Type Culture Collection, the preservation date is October 10, 2023, and the preservation number is CCTCC NO: C2023302.The anti-fox skeletal muscle troponin monoclonal antibody skTn-3A4 provided by the present application can be used for preparing an enzyme-linked immunoassay kit, a colloidal gold chromatography test strip and an evanescent wave fluorescence immune sensor for detecting fox skeletal muscle troponin, so that the fox skeletal muscle troponin in food can be rapidly and sensitively detected.

This invention discloses a highly efficient heart-specific promoter, a recombinant vector containing this promoter, and their applications. The highly efficient heart-specific promoter cTnTplus provided by this invention contains the core sequence of the chicken-derived cardiac troponin T promoter and the mouse troponin 2 gene cis-regulatory motif CS-CRM4 tandemly upstream of it. This motif functions as an enhancer element. In vitro infection of rat H9C2 cardiomyocytes showed that the eGFP fluorescence intensity driven by the cTnTplus promoter was significantly higher than that of the original cTnT promoter. In vivo, after tail vein injection of AAV virus, the eGFP expression of the cTnTplus promoter in mouse hearts was significantly increased compared to the cTnT promoter, and no obvious fluorescence was observed in liver tissue, indicating a significant reduction in liver leakage. The promoter provided by this invention possesses both high transcriptional activity and myocardial specificity, providing a safe and efficient tool for cardiac gene therapy.

The invention discloses a microRNA (Ribonucleic Acid) prediction model and a prediction kit for identifying myocardial infarction. According to the invention, six microRNAs with stable and specific expression modes in peripheral blood of an AMI patient are taken as combined markers and are used for identifying the onset risk of AMI. The microRNAs may have abnormal expression before myocardial infarction attack, have good detection stability in blood, and are important supplements for myocardial necrosis markers such as traditional troponin and the like. By capturing the early expression change of microRNA in peripheral blood, high-risk individuals can be subjected to prospective identification before typical symptoms appear, and a time window is provided for active intervention.

The present disclosure provides gRNAs targeting the phospholamban (PLN) gene, expression cassettes, vectors, virions and compositions comprising the same, as well as methods useful for the treatment or prevention of heart disease. In some embodiments, the present disclosure provides expression cassettes and vectors comprising a polynucleotide encoding a Cas endonuclease protein operably linked to a protein expression-driving promoter (e.g., a human troponin T promoter) and / or a polynucleotide encoding a gRNA targeting a sequence of the PLN gene comprising a mutation or deletion operably linked to an RNA expression-driving promoter. The present disclosure also provides guide RNAs, expression cassettes, vectors, virions and compositions for specifically targeting PLN gene comprising a deletion of Arg14.

The invention discloses a cardiac troponin I detection immunosensor as well as a preparation method, a use method and application thereof, and belongs to the technical field of biomedical sensing. The cardiac troponin I detection immunosensor comprises a solid phase capture interface for fixing a sample to be detected and a liquid phase signal amplification probe for amplifying a detection signal, the solid phase capture interface comprises a platinum single atom-nitrogen doped carbon composite material modified on the surface of the electrode; the liquid phase signal amplification probe comprises a gold nanoparticle-MXene composite material; the invention also discloses a preparation method, a use method and application of the cardiac troponin I detection immunosensor. The cardiac troponin I detection immunosensor provided by the invention has high specificity and sensitivity, and can realize rapid detection of cardiac troponin I contained in saliva so as to carry out rapid preliminary triage and risk stratification on various heart physical states.

The invention belongs to the technical field of biological detection, and particularly discloses an SERRS detection method of cardiac troponin T based on an antibody directional coupling strategy. Comprising the following steps: preparing immunomagnetic beads to capture nanoparticles, preparing gold nano-sol, preparing an SERRS nano-label, preparing a sandwich structure, and detecting cTnT antigen: performing Raman detection on the sandwich structure obtained in the step S4 through a Raman spectrometer to obtain a Raman spectrum result of cTnT. The purposes of improving the antibody utilization efficiency and reducing the antibody input cost are achieved by combining a surface enhanced resonance Raman technology (SERRS) and an oriented coupling antibody strategy, and whether a patient is diagnosed with acute myocardial infarction (AMI) or not is determined by detecting cTnT; according to the method, the AMI biomarker cTnT can be rapidly detected, reliable conditions are provided for initial detection, risk stratification and prognosis monitoring of acute myocardial infarction, and meanwhile, the application potential of an SERRS technology in a biomedical actual scene is expanded.

System, methods and computer storage media are disclosed for providing a decision support tool for reducing readmissions of AMI patients through early prediction of readmission. An AMI patient may be identified using a working diagnosis and / or an elevated troponin level. One or more machine learning models may be utilized to predict readmission at a time prior to discharge. Based on the prediction, an intervening action may be automatically initiated. Further embodiments include training machine learning model(s) to predict readmission of an AMI patient. In some embodiments, a first model may be trained using reference patient data as it existed at a predetermined time following the patient's admission (e.g., 12 hours after admission), and a second model may be trained using reference patient data as it existed at a later time (e.g., discharge). Readmission risk scores from each model may be combined to determine an overall risk for an AMI patient.

The invention relates to a multi-mode fusion portable myocardial infarction monitoring method and system, and belongs to the field of medical health monitoring. The method comprises the following steps: collecting physiological signals by using a percutaneous troponin cTnI sensor, an electrocardiogram ECG sensor, a photoelectric volume pulse wave PPG sensor, a blood pressure sensor and a body temperature sensor, and classifying and labeling the signals; removing environmental noise and baseline drift in the signal by adopting noise-reduction steady-base empirical transform DEWT; performing multi-scale decomposition on the denoised signal by using STFDE, screening IMF components with high correlation with the original signal, and performing signal reconstruction after removing low-correlation components; an ABIGRU-Reformer model is constructed, and the model is optimized in combination with an improved index triangle optimization algorithm; carrying out training set-test set division on the processed signal, training by using the optimized model, and evaluating the generalization ability of the model; in the real-time monitoring process, the preprocessed physiological signals are input into the trained model, and finally a myocardial infarction risk assessment result is output, so that early warning and real-time monitoring are realized.

Provided are a cardiac troponin I fragment, a product prepared using same, and the use thereof. The specific technical solution comprises: a cTnI (31-164) protein fragment, an HSP65 (187-375) protein fragment, and a protein fragment combination. Provided is a protein antigen or composition which can be used for detecting acute myocardial infarction, has ideal detection specificity and sensitivity, and can be further prepared into a related reagent or kit on the basis of need.

The present disclosure provides gRNAs targeting the phospholamban (PLN) gene, expression cassettes, vectors, virions and compositions comprising the same, as well as methods useful for the treatment or prevention of heart disease. In some embodiments, the present disclosure provides expression cassettes and vectors comprising a polynucleotide encoding a Cas endonuclease protein operably linked to a protein expression-driving promoter (e.g., a human troponin T promoter) and / or a polynucleotide encoding a gRNA targeting a sequence of the PLN gene comprising a mutation or deletion operably linked to an RNA expression-driving promoter. The present disclosure also provides guide RNAs, expression cassettes, vectors, virions and compositions for specifically targeting PLN gene comprising a deletion of Arg14.

The invention discloses a prediction model and a kit for identifying the recurrence risk of myocardial infarction. Different from traditional lagging diagnosis means depending on electrocardiogram abnormity or troponin rise after AMI attack, the scheme of the invention can provide risk early warning before patients have typical recurrent symptoms by detecting abnormal expression of microRNA in blood, so as to realize prospective dynamic monitoring of people with high recurrent risk. Meanwhile, direct comparison between'first AMI non-relapse patients' and'relapse patients' is adopted, and basic cardiovascular disease background interference caused by comparison only by healthy people is avoided, so that the screened marker has higher relapse event specificity, and the prediction sensitivity and accuracy are remarkably improved.

The invention discloses an antibody for resisting cardiac troponin I, and relates to the field of antibodies. The anti-cardiac troponin I antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of cardiac troponin I, and has good specificity and activity.

The invention discloses application of a flavonoid compound or pharmaceutically acceptable salt or solvate thereof in preparation of a medicine for preventing, delaying and / or treating myocardial injury and / or heart aging. The flavonoid compound has a structure as shown in a formula (I). The flavonoid compound can increase the activity of cardiac muscle cells, inhibit the active oxygen level of the cardiac muscle cells, reduce the aging positive rate of the cardiac muscle cells, relieve neutrophil infiltration and muscle fiber breakage of cardiac muscle tissues and reduce the expression level of brain natriuretic peptide (BNP) and troponin T (cTnT) in serum. (I)